Merck Sharp + Dohme Corp.

Merck Canada Inc.

Msd R&d (china) Co., Ltd.

Iomet Pharma Ltd.

Msd R&d Co., Ltd.

David Jonathan Bennett

John A McCauley

Peter D Williams

Christopher James Bungard

Yongxin Han

Oscar Miguel Moradei

Michael T Rudd

Thomas J Greshock

Zhaoyang Meng

Nigel J Liverton

Shawn J Stachel

Paul Tempest

M Katharine Holloway

Michael P Dwyer

Bin Hu

Hongjun Zhang

David L Sloman

Sherman Tim Waddell

Gregori J Morriello

Derun Li

Xin-Jie Chu

Kartik M Keertikar

Lehua Chang

Hua Zhou

Amjad Ali

Alexander Pasternak

Michael D Altman

Qun Dang

Xianhai Huang

Kun Liu

Wensheng Yu

Dong-Ming Shen

John S Wai

Maria Emilia Di Francesco

Alan B Northrup

Philippe G Nantermet

Liangqin Guo

Solomon D Kattar

Andrew M Haidle

Peter J Manley

Yongqi Deng

Abdelghani Achab

James Patrick Jewell

Craig R Gibeau

Xavier Fradera

Christian Fischer

John Michael Ellis

Qinglin Pu

Brandon Mitsuo Taoka

Kausik K Nanda

Satyanarayana Tummanapalli

Vouy Linh Truong

Christian Beaulieu

Carmela Molinaro

Sheldon N Crane

Jenny Wai

Catherine M Wiscount

Edward J Brnardic

Jiuxiang Zhu

Xuewang Xu

Daniel Mckay

Tao Ji

Bin Zhong

H Marie Loughran

Bin Zhu

Indu T Bharathan

Jesse J Manikowski

Katharine M Holloway

Christian Nadeau

Vijayasaradhi Sivalenka

William D Shipe

Min Lu

Nicolas Zorn

Anthony Donofrio

Corey E Bienstock

Ronald K Chang

Kerrie Spencer

Edward C Sherer

Alan Wise

Graham Frank Smith

Alejandro Crespo

Adam J Schell

Scott Peterson

Brett A Hopkins

Karine M Villeneuve

Sulagna Sanyal

Stephanie Lessard

Daniel McKay

Daniel Simard

Denis Deschenes

Jessie J Manikowski

Jurgen Schultz

Helen Juteau

Li Hao

Kate Holloway

Chuanman Huang

Sanjay Kumar Singh

Sivalenka Vijayasaradhi

Jurgen Schulz

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors

In its many embodiments, the present invention provides certain substituted aryl and heteroaryl ether compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides certain substituted N-aryl and N-heteroaryl piperidine compounds of the Formula (I): 

N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Piperidine derivatives as liver X receptor beta agonists, compositions, and their use

In its many embodiments, the present invention provides certain substituted bispiperidinyl compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein ring A, ring B, R, R, R, L, R, X, Z, Li, Q and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-&#x3b2; receptor (LXR&#x3b2;) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease. 

Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use

The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. 

Piperazine derivatives as HIV protease inhibitors

The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z, Z, V, V, V, R, R, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. 

HIV protease inhibitors

The present invention is directed to piperazine derivatives, pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, or are prodrugs thereof, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis and cancer.

Bipyridylaminopyridines as Syk inhibitors

Growing community of inventors

Winchester, MA, United States of America

David Jonathan Bennett